Biocompatible Glycol Chitosan Microgels as Effective Drug Carriers.
antioxidant activity
drug delivery system
glycol chitosan microsphere
natural polymeric drug carriers
tannic acid
Journal
Gels (Basel, Switzerland)
ISSN: 2310-2861
Titre abrégé: Gels
Pays: Switzerland
ID NLM: 101696925
Informations de publication
Date de publication:
10 May 2023
10 May 2023
Historique:
received:
04
04
2023
revised:
03
05
2023
accepted:
08
05
2023
medline:
26
5
2023
pubmed:
26
5
2023
entrez:
26
5
2023
Statut:
epublish
Résumé
Glycol chitosan (GC) is a chitosan (CH) derivative with improved water solubility with regards to CH which affords significant solubility advantages. In this study, microgels of GC as p(GC) were synthesized by a microemulsion technique at various crosslinking ratios e.g., 5%, 10%, 50%, 75%, and 150% based on the repeating unit of GC using divinyl sulfone (DVS) as a crosslinker. The prepared p(GC) microgels were tested for blood compatibility and it was found that p(GC) microgels at 1.0 mg/mL concentration possessed a 1.15 ± 0.1% hemolysis ratio and 89 ± 5% blood clotting index value confirming their hemocompatibility. In addition, p(GC) microgels were found biocompatible with 75.5 ± 5% cell viability against L929 fibroblasts even at a 2.0 mg/mL concentration. By loading and releasing tannic acid (TA) (a polyphenolic compound with high antioxidant activity) as an active agent, p(GC) microgels' possible drug delivery device application was examined. The TA loading amount of p(GC) microgels was determined as 323.89 mg/g, and TA releases from TA loaded microgels (TA@p(GC)) were found to be linear within 9 h and a total amount of TA released was determined as 42.56 ± 2 mg/g within 57 h. According to the Trolox equivalent antioxidant capacity (TEAC) test, 400 µL of the sample added to the ABTS+ solution inhibited 68.5 ± 1.7% of the radicals. On the other hand, the total phenol content (FC) test revealed that 2000 μg/mL of TA@p(GC) microgels resulted in 27.5 ± 9.5 mg/mL GA eq antioxidant properties.
Identifiants
pubmed: 37232990
pii: gels9050398
doi: 10.3390/gels9050398
pmc: PMC10217477
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Clin Cancer Res. 2004 Aug 1;10(15):5271-81
pubmed: 15297431
Materials (Basel). 2020 Jul 20;13(14):
pubmed: 32698426
Molecules. 2017 Oct 05;22(10):
pubmed: 28981451
ACS Nano. 2011 Dec 27;5(12):9592-601
pubmed: 22035454
Pharmaceutics. 2023 Jan 23;15(2):
pubmed: 36839706
Biomacromolecules. 2020 Feb 10;21(2):999-1008
pubmed: 31940199
J Control Release. 2012 Feb 10;157(3):493-9
pubmed: 21945679
Int J Biol Macromol. 2019 Dec 1;141:85-97
pubmed: 31473314
Bioconjug Chem. 2010 Apr 21;21(4):578-82
pubmed: 20201550
Biomacromolecules. 2008 Jul;9(7):1837-42
pubmed: 18540644
J Control Release. 2007 Nov 6;123(2):109-15
pubmed: 17894942
Colloids Surf B Biointerfaces. 2019 Dec 1;184:110505
pubmed: 31546221
Molecules. 2019 Nov 29;24(23):
pubmed: 31795385
Acta Biomater. 2019 Aug;94:2-10
pubmed: 31226480
Biomaterials. 2011 Aug;32(22):5252-61
pubmed: 21513975
ACS Appl Mater Interfaces. 2016 Feb 10;8(5):3182-92
pubmed: 26760672
J Control Release. 2014 Nov 10;193:202-13
pubmed: 24845129
J Control Release. 2008 May 8;127(3):208-18
pubmed: 18336946
J Control Release. 2002 Apr 23;80(1-3):87-100
pubmed: 11943390
Acta Biomater. 2018 Mar 15;69:256-264
pubmed: 29374599
Acc Chem Res. 2011 Oct 18;44(10):1018-28
pubmed: 21851104
Biomedicines. 2022 Aug 23;10(9):
pubmed: 36140156
Int J Biol Macromol. 2013 Aug;59:46-58
pubmed: 23608103
Langmuir. 2019 Feb 19;35(7):2610-2618
pubmed: 30673276
Expert Opin Drug Metab Toxicol. 2005 Jun;1(1):33-48
pubmed: 16922651
J Control Release. 2010 Oct 15;147(2):253-60
pubmed: 20624433
J Control Release. 2007 Oct 8;122(3):305-14
pubmed: 17643545
Adv Mater. 2020 Dec;32(51):e2002197
pubmed: 33051905
Acta Pharm Sin B. 2021 Aug;11(8):2585-2604
pubmed: 34522599
Front Bioeng Biotechnol. 2018 Jul 16;6:99
pubmed: 30062094
Biomaterials. 2017 Feb;116:1-9
pubmed: 27912130
J Immunol Methods. 1983 Dec 16;65(1-2):55-63
pubmed: 6606682
Mar Drugs. 2014 Dec 17;12(12):6038-57
pubmed: 25522316
J Control Release. 2012 Oct 28;163(2):249-55
pubmed: 22902594
Sci Rep. 2020 Jun 9;10(1):9291
pubmed: 32518266
Expert Opin Drug Deliv. 2012 Jun;9(6):687-700
pubmed: 22519507
Biomacromolecules. 2005 Mar-Apr;6(2):1154-8
pubmed: 15762689
Int J Pharm. 2012 Feb 28;423(2):452-60
pubmed: 22212463
Clin Pharmacokinet. 1999 May;36(5):353-73
pubmed: 10384859
MethodsX. 2019 Jan 10;6:156-161
pubmed: 30733928
Biomacromolecules. 2006 Dec;7(12):3452-9
pubmed: 17154474
Toxicol In Vitro. 2015 Apr;29(3):638-46
pubmed: 25482991
Front Immunol. 2020 Jun 26;11:1142
pubmed: 32676074
Food Chem. 2023 Mar 1;403:134236
pubmed: 36162263
Biomacromolecules. 2011 Jun 13;12(6):2335-43
pubmed: 21506550
ACS Appl Mater Interfaces. 2022 Apr 13;14(14):15927-15941
pubmed: 35352893
Biomed Pharmacother. 2022 Oct;154:113561
pubmed: 36029537
Adv Clin Chem. 2015;71:157-70
pubmed: 26411414
Toxicol In Vitro. 2000 Aug;14(4):345-9
pubmed: 10906441
Biomaterials. 2019 Jan;188:83-95
pubmed: 30339942
Annu Rev Biomed Eng. 2012;14:1-16
pubmed: 22524388
Biomacromolecules. 2011 Jul 11;12(7):2440-6
pubmed: 21657799
J Pharm Sci. 2014 Aug;103(8):2296-306
pubmed: 24916193